Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Pilot Study Comparing Two Different Sirolimus-based Transition Regimens in African-American Renal Transplant Recipients
Brief Summary: This study's focus is to compare the level effectiveness and safety of regimens involving Sirolimus, Cellcept and steroid to Prograf, Sirolimus and steroid in African-American recipients of kidney transplants.


Options:
A: Inclusion Criteria:

* End-stage renal disease, with patients receiving a primary or secondary renal allograft from a cadaveric donor, from a living-unrelated donor, or from a living-related (excluding 0 antigen mismatch) donor.
* Women who are of childbearing potential must have a negative pregnancy test before sirolimus administration and agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months following discontinuation of sirolimus

Exclusion Criteria:

* Evidence of active systemic or localized major infection at the time of initial sirolimus administration
* Evidence of infiltrate, cavitation, or consolidation on chest x-ray obtained during pre-study screening.
* Chronic antiarrhythmic therapy for ventricular arrhythmia or other cardiac abnormality contraindicating general anesthesia or surgery
B: Inclusion Criteria:

* Male or female patients between 18 - 75 years
* Recipients of single-organ renal primary allograft or second renal transplants (provided that the previous graft was not lost from acute rejection within the first year) from living or cadaver donors
* Patients who provide written informed consent.

Exclusion Criteria:

* PRA \> 20% within 6 months prior to enrollment
* Cold ischemia time \> 30 hours
* Previous treatment with daclizumab
* History of malignancy (except localized skin cancer)
* Active peptic ulcer disease.
C: Inclusion Criteria:

* At least 18 years of age and able to give informed consent
* African-American ethnicity
* Received a first or second non-ECD cadaveric or living donor renal transplant
* Transplant occurred during the past 6 to 24 weeks
* Patient has stable graft function, defined as no change of greater than 30% of baseline serum creatinine during the past month and no acute rejection in the past 6 weeks
* Estimated GFR using the modified MDRD equation of at least 40 mL/min10 at time of enrollment into the study
* Currently receiving tacrolimus, mycophenolate mofetil (at least 1 gm per day), and corticosteroids as their immunosuppression regimen.

Exclusion Criteria:

* Biopsy proven acute rejection episode that occurred within the past 6 weeks
* Malignancy within the past 3 years, except for non-melanoma skin cancer
* Any known intolerances to current immunosuppressant regimen necessitating withdrawal of the offending agent
* Currently enrolled in an investigational trial
* Woman of child bearing potential not utilizing an effective form of birth control
* Patients with uncontrolled dyslipidemia, defined at serum fasting LDL \>200 mg/dL or serum fasting triglycerides \>500 mg/dL.
* Patients with a spot urine protein to creatinine ratio of \> 800 mg of protein per gram of creatinine.
* WBC \< 3,000 cells/mm3
* Platelets \< 100,000 cells/mm3
D: Inclusion Criteria:

* Patients, 18 years or older, on triple maintenance therapy with cyclosporine or tacrolimus , MMF and steroids
* Informed consent

Exclusion Criteria:

* Calculated creatinine clearance \< 30 ml/min
* Multi-organ recipients
* Patients with a (historic) panel reactive antibody (PRA) \>60%
* Third renal transplant or more.
* Patients receiving investigational drugs other than MMF in combination with cyclosporine or tacrolimus
* Solid malignancy, post-transplant lymphoproliferative disease.

Answer: C